Sood A, Sidhu S S, Midha V, Jyoti D
Dept of Medicine, Dayanand Medical College and Hospital, Ludhiana, India.
J Assoc Physicians India. 1999 Feb;47(2):205-8.
There are conflicting reports on the prevalence of hepatitis B and C virus (HBV and HCV) mediated chronic liver disease (CLD) in India.
To study the prevalence of HBV and HCV associated in CLD in north India.
Eighty five patients (66 males, 19 females; age range 16-70 years) with unequivocal CLD were analysed. CLD patients with nonviral aetiologies were excluded. All sera were tested for anti-HCV by EIA (third generation), HBsAg, IgM and IgG anti-HBc, HBeAg/Anti-HBe by EIA (Abbott Diagnostics, IL). Positive anti-HCV results were confirmed by RIBA-II assay.
Sixteen (18.8%), 22 (25.9%) and 21 (24.7%) patients had HBV, HCV and HBV + HCV infection, respectively. Twenty six (30.6%) CLD patients had no viral markers.
HCV is emerging as an important cause of CLD in India. Dual infection (HBV + HCV) is seen in 25% patients. Dual infection influences the prognosis and response rates to interferon therapy.
关于印度乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)介导的慢性肝病(CLD)的患病率,存在相互矛盾的报道。
研究印度北部CLD中HBV和HCV的患病率。
分析了85例明确诊断为CLD的患者(66例男性,19例女性;年龄范围16 - 70岁)。排除非病毒病因的CLD患者。所有血清均通过酶免疫测定法(第三代)检测抗HCV、HBsAg、IgM和IgG抗HBc、HBeAg/抗HBe(雅培诊断公司,伊利诺伊州)。抗HCV阳性结果通过重组免疫印迹法(RIBA-II)进行确认。
分别有16例(18.8%)、22例(25.9%)和21例(24.7%)患者感染了HBV、HCV和HBV + HCV。26例(30.6%)CLD患者没有病毒标志物。
HCV正在成为印度CLD的一个重要病因。25%的患者存在双重感染(HBV + HCV)。双重感染会影响干扰素治疗的预后和有效率。